section name header

Front Matter

% CIpercentage confidence interval
ADHDattention deficit hyperactivity disorder
AMPAα-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
APAAmerican Psychiatric Association
BDDbody dysmorphic disorder
BINDbenzodiazepine-induced neurological dysfunction
BNFBritish National Formulary
BZDbenzodiazepine
BzRAsbenzodiazepine receptor agonists
CABGcoronary artery bypass graft
CANMATCanadian Network for Mood and Anxiety Treatments
CBTcognitive behavioural therapy
CBT-Icognitive behavioural therapy for insomnia
CFSchronic fatigue syndrome
CNScentral nervous system
COPDchronic obstructive pulmonary disease
CRcontrolled release
CSMCommittee on the Safety of Medicines
DATdopamine transporter
DAWSSDiscriminatory Antidepressant Withdrawal Symptom Scale
DESSdiscontinuation-emergent signs and symptoms
DSM-III-RDiagnostic and Statistical Manual of Mental Disorders 3rd revised edition
DSM-VDiagnostic and Statistical Manual of Mental Disorders 5th revised edition
EMAEuropean Medicines Agency
EMPOWEREliminating Medications Through Patient Ownership of End Results
ERextended release
FDAUS Food and Drugs Administration
FNDfunctional neurological disorder
GABAgamma-aminobutyric acid
GABAA gamma-aminobutyric acid type A receptor
GADgeneralised anxiety disorder
GMCGeneral Medical Council
GPgeneral practitioner
HAM-AHamilton Anxiety Rating Scale
HAM-DHamilton Depression Rating Scale
HPAhypothalamic-pituitary-adrenal
IBSirritable bowel syndrome
ICD-10-CMThe International Classification of Diseases, 10th Revision, Clinical Modification
IRimmediate-release
LGIBlower gastrointestinal bleeds
MADRSMontgomery-&angstsberg Depression Rating Scale
MAOmonoamine oxidase
MAOImonoamine oxidase inhibitor
MB-CTmindfulness based cognitive therapy
MDDmajor depressive disorder
MDMA3,4-methylenedioxymethamphetamine
MHRAMedicines and Healthcare Products Regulatory Agency
MMSEMini Mental State Examination
MUSmedically unexplained symptoms
NaSSAsnoradrenaline and specific serotonergic antidepressants
NETnoradrenaline transporter
NEWTNorth East Wales NHS Trust
NGOnon-governmental organisation
NHSNational Health Service
NICENational Institute for Health and Care Excellence
NIDANational Institute on Drug Abuse
NMDAN-methyl-D-aspartate
NNTnumber needed to treat
NPSNational Prescribing Service
OCDobsessive compulsive disorder
ODVO-desmethylvenlafaxine
ONSOffice of National Statistics
ORodds ratio
PAWSpost-acute withdrawal syndrome
PDpanic disorder
PETpositron-emission tomography
PILpatient information leaflet
PPWSpersistent post-withdrawal syndrome
PSSDpost-SSRI sexual dysfunction
PTSDpost-traumatic stress disorder
PWSpersistent withdrawal symptoms
RCPsychRoyal College of Psychiatrists
RCTrandomised controlled trial
RIMAreversible inhibitor of monoamine oxidase A
RLSrestless leg syndrome
ROreceptor occupancy
RPSRoyal Pharmaceutical Society
SADsocial anxiety disorder
SARIserotonin antagonist and reuptake inhibitors
SERTserotonin transporter
SIADHsyndrome of inappropriate secretion of antidiuretic hormone
SMDstandardised mean difference
SmPCsummary of product characteristics
SNRIserotonin and norepinephrine reuptake inhibitor
SRsustained-release
SSRIselective serotonin reuptake inhibitor
STOPPScreening Tool of Older Persons' Prescriptions
TCAstricyclic antidepressants
TIThe Therapeutics Initiative
TIAtransient ischaemic attack
UGIBupper gastrointestinal bleeds
WHOWorld Health Organization
XR or XLextended-release
Z-drugsnonbenzodiazepine sedative-hypnotics